U.S. markets closed
  • S&P 500

    4,071.70
    -4.87 (-0.12%)
     
  • Dow 30

    34,429.88
    +34.87 (+0.10%)
     
  • Nasdaq

    11,461.50
    -20.95 (-0.18%)
     
  • Russell 2000

    1,892.84
    +11.16 (+0.59%)
     
  • Crude Oil

    80.34
    -0.88 (-1.08%)
     
  • Gold

    1,811.40
    -3.80 (-0.21%)
     
  • Silver

    23.35
    +0.51 (+2.25%)
     
  • EUR/USD

    1.0531
    +0.0002 (+0.02%)
     
  • 10-Yr Bond

    3.5060
    -0.0230 (-0.65%)
     
  • GBP/USD

    1.2296
    +0.0040 (+0.33%)
     
  • USD/JPY

    134.2900
    -1.0160 (-0.75%)
     
  • BTC-USD

    16,962.95
    -35.13 (-0.21%)
     
  • CMC Crypto 200

    404.33
    +2.91 (+0.72%)
     
  • FTSE 100

    7,556.23
    -2.26 (-0.03%)
     
  • Nikkei 225

    27,777.90
    -448.18 (-1.59%)
     

Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options

Webinar to be held Friday, September 23, 2022 @ 10 a.m. ET

DURHAM, N.C., September 13, 2022--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced that it will host a Key Opinion Leader (KOL) webinar on Friday, September 23, 2022 from 10:00 a.m. – 11:30 a.m. Eastern Time.

The event will feature Dr. Laura Periman, MD, of the Periman Eye Institute, and Dr. John Sheppard, MD, of the Virginia Eye Consultants, who will discuss New Perspectives on Dry Eye Disease (DED), including the Current Landscape, Unmet Medical Needs, and Emerging Treatment Options, including Aerie’s investigational TRPM8 agonist, AR-15512.

AR-15512 is currently undergoing Phase 3 registrational trials for the treatment of DED. Aerie’s leadership team will provide a brief overview of AR-15512 and an update on the Phase 3 registrational program during the webinar.

To register for the event, please click here.

About the KOLs

Laura Periman, M.D.

Dr. Periman is a Cornea and Refractive Surgery Fellowship trained physician and surgeon with roots as a molecular biologist. She finds immense joy in combining her scientific interests, clinical interests, and creativity into start-up collaborative projects, advanced medical education projects as well as innovative, state of the art clinical care. Her passion for understanding the immunopathophysiology and treatment of diseases has its roots in her experiences as a Molecular Biology Research and Development Associate at Immunex Corporation (now Amgen) prior to medical school. She has a talent for applying basic science to clinical medicine, and teaching a wide variety of audiences with a sense of discovery, forward thinking, and a healthy dose of fun. Dr. Periman is a dry eye expert who has spent years in private practices focusing on the disease, before opening and running the Periman Eye Institute.

John Sheppard, M.D.

Dr. John Sheppard is a Board Certified Ophthalmologist and fellowship-trained corneal eye surgeon. As the President of Virginia Eye Consultants, Dr. Sheppard oversees their overall mission of providing a leading academic, clinical, and research center for excellence in ophthalmology. He is committed to providing the highest quality eye care solutions and is widely regarded as a leader in his field. Dr. Sheppard is actively involved in numerous clinical trials and has participated as principal investigator in over 120 clinical research trials sponsored by many major pharmaceutical companies and for the U.S. Food and Drug Administration (FDA). In addition, Dr. Sheppard has served on the medical advisory board for over 81 pharmaceutical and medical device companies. He has authored over 115 peer review abstracts, journal articles, and chapters.

About Aerie Pharmaceuticals, Inc.

Aerie is a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, diabetic macular edema (DME), and wet age-related macular degeneration (wet AMD). Aerie’s product portfolio includes two FDA approved products and a pipeline of three product candidates in clinical development. Aerie’s novel product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil (0.02%) and latanoprost ophthalmic solution (0.005%)), was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan®, including the product label, is available at www.rocklatan.com. Aerie’s novel product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the FDA for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa®, including the product label, is available at www.rhopressa.com. More information on Aerie Pharmaceuticals is available at www.aeriepharma.com.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "exploring," "pursuing" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements in this release include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our commercial franchise and our pipeline, and our ongoing and anticipated preclinical studies and clinical trials, including Phase 3 registrational trials for AR-15512. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, industry change, and other factors beyond our control and depend on regulatory approvals and macroeconomic and other environmental circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We discuss many of these risks in greater detail under the heading "Risk Factors" in the quarterly and annual reports that we file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005081/en/

Contacts

Media: Carolyn McAuliffe
cmcauliffe@aeriepharma.com
(949) 526-8733

Investors: LifeSci Advisors on behalf of Aerie Pharmaceuticals, Inc.
Hans Vitzthum
hans@lifesciadvisors.com
(617) 430-7578